Evidence map›Paper›PMID 39177879›Full record

Trial reportInternational journal of clinical oncology2024

Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.

Hajime Hosoi, Mitsuru Miyachi, Satoshi Teramukai, Satomi Sakabayashi, Kunihiko Tsuchiya, Yasumichi Kuwahara, Rie Onodera, Kotone Matsuyama, Isao Yokota, Hiroshi Hojo and 19 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Hajime HosoiDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine (KPUM), Kyoto, Japan. hhosoi@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0002-8345-0159
Mitsuru MiyachiDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine (KPUM), Kyoto, Japan.
Satoshi TeramukaiDepartment of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Satomi SakabayashiDepartment of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kunihiko TsuchiyaDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine (KPUM), Kyoto, Japan.
Yasumichi KuwaharaDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine (KPUM), Kyoto, Japan.
Rie OnoderaTranslational Research Informatics Center, Kobe, Japan.
Kotone MatsuyamaTranslational Research Informatics Center, Kobe, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi HojoDepartment of Diagnostic Pathology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hajime OkitaDivision of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan.
Jun-Ichi HataExperimental Medicine and Life Science, Kanagawa, Japan.
Minori HamasakiDepartment of Pathology, Shizuoka Children's Hospital, Shizuoka, Japan.
Masazumi TsuneyoshiDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Atsuko NakazawaDepartment of Pathology, Saitama Children's Medical Center, Saitama, Japan.
Miho KatoChildhood Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Tetsuya TakimotoChildhood Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Keizo HoribeClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Jun-Ichi HaraDepartment of Pediatric Hematology/Oncology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
Sachiyo SuitaDepartment of Pediatric Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Ryoji HanadaDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Hidekazu MasakiDepartment of Radiology, National Center for Child Health and Development (NCCHD), Tokyo, Japan.
Miwako NozakiDepartment of Radiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Hitoshi IkedaDepartment of Pediatric Surgery, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Seiji KishimotoDepartment of Otolaryngology, Head and Neck Surgery, Kameda Medical Center, Chiba, Japan.
Michio KanekoDepartment of Pediatric Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
Akira KawaiDepartment of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yasuhide MorikawaDepartment of Pediatric Surgery, International University of Health and Welfare Hospital, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development JP19ck0106333Japan Agency for Medical Research and Development JP20ck0106610
6 · The paper itself

Abstract

backgroundFailure-free survival (FFS) rates of low-risk patients with rhabdomyosarcoma improved in Intergroup Rhabdomyosarcoma Study IV after the escalation of cyclophosphamide total dose to 26.4 g/m

methodsSubgroup-A patients received eight cycles (24 weeks) of vincristine, actinomycin D, and 1.2 g/m

resultsIn subgroup A (n = 12), the 3-year FFS rate was 83% (95% confidence interval [CI], 48-96), and the 3-year overall survival (OS) rate was 100%. Only one isolated local recurrence was observed (8.3%). There were no unexpected grade-4 toxicities and no deaths. In subgroup B (n = 16), the 3-year FFS and OS rates were 88% (95% CI, 59-97) and 94% (95% CI, 63-99), respectively. There were no unexpected grade 4 toxicities and no deaths.

conclusionsShorter duration therapy using vincristine, actinomycin D, and lower dose cyclophosphamide with or without radiotherapy for patients with low-risk subgroup A rhabdomyosarcoma (JRS-I LRA0401 protocol) and moderate reduction of cyclophosphamide dose for patients with low-risk subgroup B rhabdomyosarcoma (JRS-I LRB0402 protocol) did not compromise FFS.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDactinomycinRhabdomyosarcoma, EmbryonalVincristineAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleHumansJapanMaleYoung AdultCyclophosphamideDactinomycinVincristineCentral pathology review systemEmbryonal rhabdomyosarcomaLow riskNationwide group studyRisk-adopted therapy

Identifiers

PMID39177879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.